{"id":"https://openalex.org/W193297271","doi":"https://doi.org/10.1182/blood.v124.21.2208.2208","title":"Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies","display_name":"Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W193297271","doi":"https://doi.org/10.1182/blood.v124.21.2208.2208","mag":"193297271"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.2208.2208","doi":"https://doi.org/10.1182/blood.v124.21.2208.2208","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.2208.2208","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038643879","display_name":"William T. Senapedis","orcid":"https://orcid.org/0009-0004-1566-2733","observed_orcids":["https://orcid.org/0009-0004-1566-2733"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Senapedis","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ryan George","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan George","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017267359","display_name":"Dilara McCauley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dilara McCauley","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103725544","display_name":"Joel Ellis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joel Ellis","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084986364","display_name":"Marsha L. Crochiere","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marsha Crochiere","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Savona","raw_affiliation_strings":["Vanderbilt University School of Medicine, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University School of Medicine, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051352882","display_name":"Sharon Shacham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon Shacham","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057755017","display_name":"Yosef Landesman","orcid":"https://orcid.org/0000-0001-5542-5098","observed_orcids":["https://orcid.org/0000-0001-5542-5098"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yosef Landesman","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067532930","display_name":"Erkan Baloglu","orcid":"https://orcid.org/0000-0002-4106-732X","observed_orcids":["https://orcid.org/0000-0002-4106-732X"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erkan Baloglu","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.1366,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.47615046,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"124","issue":"21","first_page":"2208","last_page":"2208"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.8125,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.8125,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.03680000081658363,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.03590000048279762,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pak4","display_name":"PAK4","score":0.8759999871253967},{"id":"https://openalex.org/keywords/p21-activated-kinase","display_name":"p21-activated kinase","score":0.8429999947547913},{"id":"https://openalex.org/keywords/allosteric-modulators","display_name":"allosteric modulators","score":0.9559999704360962},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.847000002861023},{"id":"https://openalex.org/keywords/t-cell-acute-lymphoblastic-leukemia","display_name":"T-cell acute lymphoblastic leukemia","score":0.8650000095367432},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.7799999713897705},{"id":"https://openalex.org/keywords/kpt-9274","display_name":"KPT-9274","score":0.9819999933242798},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7829999923706055},{"id":"https://openalex.org/keywords/autophagy","display_name":"autophagy","score":0.8529999852180481},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.6840000152587891},{"id":"https://openalex.org/keywords/caspase-activation","display_name":"caspase activation","score":0.6669999957084656},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6063370704650879},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.490596204996109},{"id":"https://openalex.org/C166342909","wikidata":"https://www.wikidata.org/wiki/Q845326","display_name":"Allosteric regulation","level":3,"score":0.48207026720046997},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.43871334195137024},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.4351709485054016},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.4226207733154297},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4152829945087433},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.41514289379119873},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.40065479278564453},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.38837945461273193},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38084644079208374},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3671916127204895},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.33019083738327026},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.32670554518699646},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.20121154189109802},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.2208.2208","doi":"https://doi.org/10.1182/blood.v124.21.2208.2208","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.2208.2208","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1481436129","https://openalex.org/W184801531","https://openalex.org/W2553016719","https://openalex.org/W2740643100","https://openalex.org/W3208779542","https://openalex.org/W2571809330","https://openalex.org/W2558460087","https://openalex.org/W4293427387","https://openalex.org/W2482181055","https://openalex.org/W2605735165"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Many":[2],"hematological":[3,232,412,469],"cancers":[4],"have":[5,201,372],"been":[6],"successfully":[7],"treated":[8],"through":[9,294],"identification":[10],"of":[11,56,60,73,105,110,128,160,196,231,244,255,263,285,297,305,323,335,339,367,411,428,435,441,464,468,494,505,516,527],"specialized":[12],"targets":[13],"in":[14,22,27,48,117,185,188,193,228,252,282,320,332,385,398,407,408,448,451],"each":[15],"specific":[16],"tumor":[17,349],"subtype":[18],"(e.g.":[19],"BTK":[20],"inhibition":[21,26,440],"NHL":[23],"or":[24,115,496,507,518,529],"proteasome":[25],"multiple":[28,386],"myeloma).":[29],"The":[30,70,169],"p21-Activated":[31],"Kinase":[32],"4":[33],"(PAK4)":[34],"is":[35,53,102,113,122],"critical":[36],"to":[37,143,157,190,395],"cellular":[38],"signaling":[39,266],"and":[40,68,87,98,112,135,152,167,175,219,260,274,287,300,302,309,327,347,388,400,450],"may":[41],"represent":[42],"a":[43,54,103,124,229,279,358,363,425,465],"new":[44],"target":[45,361],"for":[46,461],"therapy":[47],"many":[49,118],"hematologic":[50],"malignancies.":[51],"PAK4":[52,101,121,208,256,356,378,417,421,436,455],"member":[55,104],"the":[57,74,106,129,176,192,253,295,333,342,368,429,442,447,462],"PAK":[58,75],"family":[59,76,109],"proteins":[61,267],"that":[62],"regulate":[63],"cell":[64,66,148,172,178,180,234,345,390,397],"survival,":[65],"division":[67],"apoptosis.":[69],"six":[71],"members":[72],"are":[77,351],"divided":[78],"into":[79],"two":[80],"groups;":[81],"Group":[82,88],"I":[83],"(PAK1,":[84],"2,":[85],"3)":[86],"II":[89,108],"(PAK4,":[90],"5,":[91],"6),":[92],"based":[93],"upon":[94],"their":[95],"sequence":[96],"homology":[97],"regulatory":[99],"mechanisms.":[100],"group":[107],"PAKs":[111],"amplified":[114],"mutated":[116],"cancer":[119,233,245],"types.":[120],"also":[123],"key":[125,264],"downstream":[126,365],"effector":[127,366],"K-Ras":[130],"pathway.":[131],"Methods:":[132],"Flow":[133],"cytometry":[134],"CellTiter":[136],"AQueous":[137],"One":[138],"(MTS)":[139],"assays":[140],"were":[141,155,183],"used":[142,156,184],"determine":[144],"compound":[145],"effects":[146,159],"on":[147,162,446,490,501,512,523],"cycle":[149],"distribution,":[150],"proliferation":[151],"viability.":[153],"Immunoblots":[154],"measure":[158],"compounds":[161,415],"protein":[163,430],"steady":[164,257],"state":[165,258],"levels":[166,259],"phosphorylation.":[168],"T-cell":[170],"ALL":[171],"line,":[173,181],"MOLT-4,":[174],"mantle":[177],"lymphoma":[179,389],"Z-138,":[182],"xenograft":[186,311],"models":[187,350,410],"mice":[189],"test":[191],"vivo":[194,409,452],"efficacy":[195],"these":[197,248,454],"compounds.":[198],"Results:":[199],"We":[200,371],"identified":[202,373],"selective,":[203,374],"orally":[204],"bioavailable,":[205],"small":[206,249,324,376],"molecule":[207,377],"allosteric":[209,290,379,456],"modulators":[210,291,380,457],"{PAMs;":[211],"e.g.":[212],"KPT-8752":[213],"(mw:":[214,217,221],"585.6),":[215],"KPT-9274":[216],"610.6),":[218],"KPT-9331":[220],"628.6)}":[222],"which":[223,381],"demonstrated":[224],"selective":[225],"anti-tumor":[226,402],"activity":[227,403],"variety":[230,467],"lines":[235,391],"(IC50":[236],"values":[237],"=":[238],"0.005":[239],"\u2013":[240],"1":[241],"mM).":[242],"Treatment":[243],"cells":[246],"with":[247,316,392,404],"molecules":[250],"resulted":[251,319],"reduction":[254],"reduced":[261],"phosphorylation":[262],"growth":[265],"such":[268],"as":[269,362],"Akt,":[270],"\u03b2-catenin,":[271],"cofilin,":[272],"p21,":[273],"cyclin":[275],"D1.":[276],"There":[277],"was":[278],"measurable":[280],"increase":[281],"phospho-AMPK":[283],"indicative":[284],"autophagy":[286],"stress.":[288],"These":[289,414],"induced":[292],"apoptosis":[293],"activation":[296],"caspases":[298],"3":[299],"8":[301],"subsequent":[303],"cleavage":[304],"PARP.":[306],"In":[307],"MOLT-4":[308],"Z-138":[310],"mouse":[312],"models,":[313],"daily":[314],"treatment":[315,463],"oral":[317],"PAMs":[318],"near":[321],"elimination":[322],"(100":[325],"mm3)":[326,330],"large":[328],"(800":[329],"tumors":[331],"absence":[334],"any":[336],"clinical":[337],"signs":[338],"toxicity":[340,394],"within":[341],"animals.":[343],"Additional":[344],"line":[346],"primary":[348],"currently":[352],"being":[353],"explored.":[354],"Conclusions:":[355],"represents":[357,424],"novel":[359,426],"anti-cancer":[360],"major":[364],"Ras":[369],"oncogene.":[370],"orally-bioavailable":[375],"induce":[382],"potent":[383],"cytotoxicity":[384],"leukemia":[387],"minimal":[393],"normal":[396],"vitro":[399,449],"clear":[401],"excellent":[405],"tolerability":[406],"cancers.":[413,470],"inactivate":[416],"by":[418],"directly":[419],"inducing":[420],"destabilization.":[422],"This":[423],"mechanism":[427],"kinase":[431,443],"inactivation":[432],"involving":[433],"degradation":[434],"rather":[437],"than":[438],"direct":[439],"activity.":[444],"Based":[445],"activity,":[453],"show":[458],"promising":[459],"results":[460],"wide":[466],"Disclosures":[471],"Senapedis:":[472],"Karyopharm:":[473],"Employment.":[474,476,483,485,534,537,539],"George:Karyopharm:":[475],"McCauley:Karyopharm":[477],"Therapeutics:":[478,533,536],"Employment,":[479],"Equity":[480,487],"Ownership.":[481],"Ellis:Karyopharm:":[482],"Crochiere:Karyopharm:":[484],"Savona:Karyopharm:":[486],"Ownership,":[488],"Membership":[489,500,511,522],"an":[491,502,513,524],"entity's":[492,503,514,525],"Board":[493,504,515,526],"Directors":[495,506,517,528],"advisory":[497,508,519,530],"committees;":[498,509,520],"Celgene:":[499],"Gilead:":[510],"Incyte:":[521],"committees.":[531],"Shacham:Karyopharm":[532],"Landesman:Karyopharm":[535],"Baloglu:Karyopharm:":[538]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}